Materialise Reports Q3 Revenue Growth Driven by Medical Segment

Materialise reported third-quarter 2026 consolidated revenue of €67.7 million, which increased more than 2% year over year. The company noted that its medical revenue grew nearly 10% year over year, driven by both medical device and medical software sales. Additionally, Materialise signed an agreement with Superhumans Center to support reconstructive surgery in its craniomaxillofacial business.

The medical segment is driving Materialise's growth, generating adjusted EBITDA of €10 million for the quarter. Despite increased research and development spending and operational one-time costs, the company expanded its gross margin to 57.7%. Materialise reaffirmed its full-year revenue and adjusted EBIT guidance.